BREAKING: Futures Rise As Oracle Skyrockets, PPI Inflation Tame Shares of Travere Therapeutics (TVTX) shot higher Wednesday after the Food and Drug Administration eliminated a key step to approving its drug, Filspari, for another kidney disease. Previously, the FDA indicated it would need to hold an advisory committee meeting to discuss the merits of Filspari in patients with focal segmental glomerulosclerosis, or FSGS. This disease causes scarring in the glomeruli, the tiny filters of the kidneys. Filspari ...